Cited by 30Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsOsteoarthritis Treatment and Mechanisms

Robust anti‐nociceptive effects of monoacylglycerol lipase inhibition in a model of osteoarthritis pain

Open access
Burston, James J, Mapp, Paul I, Sarmad, Sarir, Barrett, David A, Niphakis, Micah J, Cravatt, Benjamin F, Walsh, David A, Chapman, Victoria·2016·British Journal of Pharmacology

Abstract

Background and Purpose: Chronic pain is often a symptom of knee osteoarthritis (OA) for which current analgesics are either inadequate or are associated with serious side effects. The endocannabinoid system may offer alternative targets for pain relief. We evaluated the effects of a potent and selective monoacylglycerol (MAG) lipase inhibitor (MJN110) on OA pain behaviour, spinal mechanisms of action and joint histopathology in the rat. Experimental Approach: Intra‐articular injection of monosodium iodoacetate (MIA) models OA pain and mimics clinical joint pathology. Effects of MJN110 on MIA‐induced weight‐bearing asymmetry and lowered paw withdrawal thresholds (PWTs), changes in spinal gene expression and brain levels of relevant lipids were determined. Key Results: Acute MJN110 (5 mg·kg−1) significantly reversed MIA‐induced weight‐bearing asymmetry (MIA/vehicle: 68 ± 6 g; MIA/MJN110: 35 ± 4 g) and lowered ipsilateral PWTs (MIA/vehicle: 7 ± 0.8 g; MIA/MJN110: 11 ± 0.6 g), via both CB 1 and CB 2 receptors. Repeated treatment with MJN110 (5 mg·kg−1) resulted in anti‐nociceptive tolerance. A lower dose of MJN110 (1 mg·kg−1) acutely inhibited pain behaviour, which was maintained for 1 week of repeated administration but had no effect on joint histology. MJN110 significantly inhibited expression of membrane‐associated PGE synthase‐1 in the ipsilateral dorsal horn of the spinal cord of MIA rats, compared with vehicle‐treated MIA rats. Both doses of MJN110 significantly elevated brain levels of the endocannabinoid 2‐arachidonoylglycerol. Conclusions and Implications: Our data support further assessment of the therapeutic potential of MAG lipase inhibitors for the treatment of OA pain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.13574

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Burston, J. J., Mapp, P. I., Sarmad, S., Barrett, D. A., Niphakis, M. J., Cravatt, B. F., Walsh, D. A., & Chapman, V.
Affiliations
  • University of Nottingham (GB)
  • Scripps Research Institute (US)
Corresponding author
  • Burston, James J
  • Chapman, Victoria
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2016-09-23
Volume
173
Issue
21
Pages
3134-3144
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2528493014
Cited by
30
References
45
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 1 · 2018: 4 · 2017: 5
FWCI
2.69
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (publishedVersion, other-oa)
  • Lincoln Repository (University of Lincoln) (acceptedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
Funders
Versus Arthritis (18769)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
Keywords
monoacylglycerol lipase inhibition, monosodium iodoacetate, endocannabinoid system, CB1 receptor, CB2 receptor, antinociception, analgesic tolerance, prostaglandin E synthase-1, dorsal horn, 2-arachidonoylglycerol, weight-bearing asymmetry, paw withdrawal threshold
MeSH terms
Analgesics, Animals, Disease Models, Animal, Enzyme Inhibitors, Injections, Intra-Articular, Male, Monoacylglycerol Lipases, Osteoarthritis, Pain, Pain Measurement, Rats, Sprague-Dawley, Iodoacetic Acid, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review